Linee guida per la riabilitazione delle malattie neuromuscolari infantili di origine genetica. G di Neuropsicofarmacol.
Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care-NC-ND license. Neuromuscul Disord. 2018;
Il- EB V, Th M. Dossier Spinraza Piemonte. 2017.
Finkel RS, Mercuri E, Meyer OH, Simonds AK, Schroth MK, Graham RJ, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018 Mar 1;
Sumner CJ, Paushkin S, Ko C. Spinal muscular atrophy : disease mechanisms and therapy.
D’Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Vol. 6, Orphanet journal of rare diseases. BioMed Central; 2011. 71 p.
Gidaro T, Servais L. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps. Dev Med Child Neurol. 2019;
Mastella C, Ottonello G. “SMA1 abita con noi”. Vademecum per una sostenibile vita quotidiana a casa. 2009.
Smartnet P. HFMSE Manual. 2009.
De Sanctis R, Coratti G, Pasternak A, Montes J, Pane M, Mazzone ES, et al. Developmental milestones in type I spinal muscular atrophy. Neuromuscul Disord. 2016;26:754–9.
Glanzman AM et A. Chop Intend manuale. Medicina. 2010.
Evaluator LC. Revised Upper Limb Module for SMA. 2014;1–21.
Bérard C, Payan C, Hodgkinson I, Fermanian J. A motor function measure scale for neuromuscular diseases. Construction and validation study. Neuromuscul Disord. 2005;15:463–70.
